We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04508140
Recruitment Status : Recruiting
First Posted : August 11, 2020
Last Update Posted : December 10, 2020
Sponsor:
Information provided by (Responsible Party):
Highlight Therapeutics

Brief Summary:

This is an open, single arm, multicenter phase 2 trial in which BO-112 will be administered intratumorally in combination with intravenous pembrolizumab in patients with liver metastasis from colorectal, gastric or gastroesophageal junction cancers. The objective is to reverse the primary resistance that a subgroup of patients from these tumors having microsatellite stability present to the PD-1 inhibitors. Treatment will be administered every 3 weeks, with the exception of the first cycle, in which BO-112 will be also administered on D8, for up to 2 years.

The primary objective is overall response rate based on RECIST 1.1 and safety, specifically referred to treatment emergent adverse events (TEAEs) with severity ≥ Grade 3 related to the study treatment (NCI-CTCAE v 5.0). The secondary endpoints include other efficacy endpoints (duration of response, disease control rate, progression-free survival, overall survival at 6 months, all based on RECIST 1.1, and overall response rate based on a specific tumor assessment criteria to evaluate the response to immunotherapies, IRECIST) and safety, in this case considering the number and proportion of subjects with treatment TEAEs (any grade) . In addition, the changes in the tumor microenvironment induced by the injection of BO-112 will be also evaluated as exploratory endpoints.


Condition or disease Intervention/treatment Phase
Colorectal Cancer Gastric Cancer Oesophageal Cancer Procedure: Hepatic Biopsy Drug: BO-112 with Pembrolizumab Phase 2

Detailed Description:

The purpose of this Phase II study is to evaluate the safety, tolerability, antitumoural activity and systemic exposure of repeated IT administrations of BO-112 percutaneously injected into a hepatic metastatic lesion in combination with pembrolizumab administered intravenously.

This is an open-label, non-comparative, 2-cohort study with a Simon's 2-stage design which will include up to 69 evaluable adult subjects with un resectable liver metastasis suitable for IT injection from CRC or GC/GEJ who are naive to anti-PD1/PDL1 therapy.

Cohort A will consist of up to 26 subjects with metastatic CRC who have received at least 2 prior standard of care systemic anticancer therapies for advanced/metastatic disease. Bevacizumab may have been previously administrated. Prior Anti-EGFR drugs are mandatory if applicable depending on the RAS status.

Cohort B will consist of up to 43 subjects with gastric or GC/GEJ who have received at least 1 prior standard of care systemic anticancer therapy for advanced/metastatic disease. Prior Her2 blockade will be mandatory in those patients with Her2 positive tumors.

The aim of this study is to reverse the primary resistance that the subgroup of patients from these 2 cohorts who present microsatellite stability (MSS), in which data from previous clinical trials have demonstrate that the inhibition of PD-1 has no proven efficacy. For that purpose, the MSI status will be determined in the pre-treatment biopsy, done on C1D1, before the first BO-112 administration. Those patients with a MSI status will continue under study treatment but will be replaced and will not be considered for the efficacy assessment, only for the safety assessment. Those patients having a MSS status will be considered bot both assessments.

The recommended dose for further clinical development of BO-112 is 1 mg administered in 1.7 mL volume, based on the data from the 112/2016-IT study, the fist-in-human trial with BO-112. The planned dose of pembrolizumab for this study is 200 mg. Study treatment will consist of BO-112 IT injections in combination with IV pembrolizumab infusions and will be administered in 3-week cycles. For each cycle, BO-112 IT injections will be administered after the pembrolizumab infusion, either the same day or within a period of up to 36 hours after the pembrolizumab infusion (for organisational feasibility at the site). On the first cycle, BO-112 will be administered on D1 and D8.

The BO-112 IT injections will be administered by an interventional radiologist under ultrasound guidance, or occasional CT scan guidance, at the discretion of the interventional radiologist.

Study treatment should continue as long as there is clinical benefit and it is tolerated, up to a maximum of approx. 2 years (corresponding to 35 treatment cycles).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 69 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open-label, non-comparative study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IIa Open-label Clinical Study of Intratumoural Administration of BO-112 in Combination With Pembrolizumab in Subjects With Liver Metastasis From Colorectal Cancer or Gastric/Gastro-oesophageal Junction Cancer
Actual Study Start Date : June 17, 2020
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Single Arm
The study treatment consists of the combination of BO-112 given intratumorally inside the liver metastasis at the dose of 1gm in 1.2 mL in combination with intravenous pembrolizumab given at the fixed dose of 200 mg. This treatment will be given every 3 weeks, with a maximum duration of 35 cycles (2 years). Of note, during the first cycle, BO-112 will be administered on D1 and D8.
Procedure: Hepatic Biopsy
In this trial a biopsy from the hepatic lesion to be injected will be mandatory on C1D1 and C2D1, prior to the BO-112 administration. On the same timepoints, a biopsy from a non-hepatic, non-injected lesion will be optional.

Drug: BO-112 with Pembrolizumab
. The study treatment consists of the combination of BO-112 given intratumorally inside the liver metastasis at the dose of 1gm in 1.2 mL in combination with intravenous pembrolizumab given at the fixed dose of 200 mg. This treatment will be given every 3 weeks, with a maximum duration of 35 cycles (2 years). Of note, during the first cycle, BO-112 will be administered on D1 and D8.




Primary Outcome Measures :
  1. Anti-tumour efficacy:overall response rate [ Time Frame: Throughout study completion, an average of 3 years. ]
    ORR based on the BOR using RECIST 1.1 of repeated IT administrations of BO-112 in metastatic liver lesions in combination with IV pembrolizumab

  2. Safety: Adverse Events [ Time Frame: Throughout study completion, an average of 3 years ]
    Number and proportion of subjects with study treatment-related TEAEs with severity Grade 3 (NCI-CTCAE v 5.0)


Secondary Outcome Measures :
  1. Disease control rate [ Time Frame: Throughout study completion, an average of 3 years ]
    Best response for CR, PR as well as stable disease (SD) using RECIST 1.1

  2. Objective response rate [ Time Frame: Throughout study completion, an average of 3 years ]
    Based on best overall response using RECIST modified for immune-based therapies (iRECIST)

  3. Disease Control Rate [ Time Frame: Throughout study completion, an average of 3 years ]
    Comprising best response for CR, PR as well as SD using iRECIST

  4. Duration of response [ Time Frame: Up to 36 months ]
    Duration of response

  5. PFS [ Time Frame: Up to 36 months ]
    Progression-free survival

  6. Survival Rate [ Time Frame: Up to 36 months ]
    Overall Survival Rate



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Nonresectable liver metastasis(es) of colorectal or gastric/gastro-oesophageal junction cancer (GC/GEJ). History of resection for liver metastasis is allowed.
  • Histological or cytological proof of colorectal (Cohort A) or GC/GEJ cancer (Cohort B).
  • Progression during or after, or have not tolerated therapy for advanced/metastatic disease as follows:

    1. Cohort A (CRC): at least 2 lines of fluoropyrimidine, irinotecan and/or oxaliplatin containing therapy with or without bevacizumab; if epidermal growth factor receptor (EGFR) positive/RAS wild type, prior anti-EGFR treatment is required. Incase of prior resection of hepatic metastasis with hepatic recurrence, only 1 prior line of fluoropyrimidine, irinotecan and/or oxaliplatin containing therapy is required.
    2. Cohort B (GC/GEJ): fluoropyrimidine and platinum containing treatment; if Human epidermal growth factor receptor 2 (HER-2) positive, also prior anti-HER-2 treatment is required.
  • At least 1 liver metastasis of minimum 20 mm in diameter that is suitable for percutaneous, IT injection .
  • Presence of at least 1 measurable lesion according to RECIST v1.1. Note: this may be the liver metastasis selected for injection if it is the only measurable lesion present.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate haematologic and end-organ function

EXCLUSION CRITERIA

  • Prior treatment with an anti-PD1, anti-PDL1 or anti-PDL2 agent, an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137) or any Toll-like receptor (TLR) agonist.
  • Liver metastasis(es) with macroscopic tumour infiltration into the main portal vein, hepatic vein or vena cava.
  • Contraindications to tumour biopsy and injections of the hepatic metastasis(es).
  • Chemotherapy, definitive (curative) radiation, or biological cancer therapy within 4 weeks prior to the first dose of study treatment.
  • Palliative radiotherapy (≤ 2 weeks of radiotherapy) within 1 week of start of study treatment.
  • Clinically active central nervous system (CNS) metastases and/or carcinomatosis meningitis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04508140


Contacts
Layout table for location contacts
Contact: Vanesa Pons, MD, PhD +34 639 664 658 vpons@highlighttherapeutics.com

Locations
Layout table for location information
Belgium
Institut Jules Bordet Recruiting
Brussels, Belgium
UCL St-Luc Recruiting
Brussels, Belgium
University Hospital Antwerp (UZA) Not yet recruiting
Edegem, Belgium
Universitair Ziekenhus Gent Not yet recruiting
Gent, Belgium
Italy
IRCCS Ospedale Policlinico San Martino Not yet recruiting
Genova, Italy
Azienda Ospedaliera Ospedale Niguarda Ca'Granda Recruiting
Milan, Italy
Spain
Hospital Reina Sofía Active, not recruiting
Córdoba, Cordoba, Spain
Hospital Valle Hebrón Recruiting
Barcelona, Spain
Hospital Gregorio Marañón Recruiting
Madrid, Spain
Hospital Ramón y Cajal Active, not recruiting
Madrid, Spain
Clínica Universitaria de Navarra Recruiting
Pamplona, Spain
Hospital Clínico de Valencia Recruiting
Valencia, Spain
Sponsors and Collaborators
Highlight Therapeutics
Investigators
Layout table for investigator information
Study Director: Vanesa Pons, MD, PhD Highlight Therapeutics
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Highlight Therapeutics
ClinicalTrials.gov Identifier: NCT04508140    
Other Study ID Numbers: BOT112-02
2019-004624-38 ( EudraCT Number )
KEYNOTE-A06 ( Other Identifier: Merck )
First Posted: August 11, 2020    Key Record Dates
Last Update Posted: December 10, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents